Strides Arcolab receives USFDA nod for Efavirenz tablets

New Delhi, Mar 28 (UNI) Strides Arcolab Ltd today said it received a tentative approval from the United States Food and Drug Administration for Efavirenz tablets under the expedited review provisions of the President's Emergency Plan for Aids Relief (PEPFAR) programme.

Efavirenz is used in combination with other anti-retroviral agents for the treatment of HIV-infections and is a key component of drug regimens for patients who are on concurrent treatment for tuberculosis.

''We now have ANDA/NDA approvals for all first line anti-retroviral drugs. This (approval) will give major boost to our Aids, TB and Malaria (ATM) initiative particularly in Africa and South Asian countries,'' company Vice Chairman and Managing Director Arun Kumar said.

The company also partners the Clinton Foundation to ensure availability of affordable quality generic ARVs in least developed countries.

UNI